Stock Events

Stock Events

Sarepta Therapeutics 

$21.79
253
-$0.25-1.13% Tuesday 20:00

Statistics

Day High
22.66
Day Low
21.04
52W High
63.66
52W Low
11.93
Volume
2,122,051
Avg. Volume
-
Mkt Cap
2.28B
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

6MayExpected
Q3 2024
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q4 2025
Next
-4.6
-2.44
-0.27
1.89
Expected EPS
0.975922
Actual EPS
N/A

Financials

12.37%Profit Margin
Profitable
2019
2020
2021
2022
2023
2024
3.8BRevenue
470.48MNet Income

Analyst Ratings

26.33Average Price Target
The highest estimate is 38.00.
From 7 ratings within the last 6 months. This is not an investment recommendation.
Buy
57%
Hold
0%
Sell
43%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow SRPT. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Pfizer
PFE
Mkt Cap149.77B
Pfizer is developing gene therapies for Duchenne muscular dystrophy (DMD), directly competing with Sarepta's DMD treatments.
Sangamo Therapeutics
SGMO
Mkt Cap55.93M
Sangamo Therapeutics is working on genomic medicines, including treatments for DMD, which competes with Sarepta's gene therapy portfolio.
Sorrento Therapeutics
SRNE
Mkt Cap275,640
Sorrento Therapeutics has a diverse pipeline including treatments for diseases that Sarepta also targets, making them competitors in the biotech space.
Biomarin Pharmaceutical
BMRN
Mkt Cap10.45B
BioMarin Pharmaceutical competes with Sarepta in the rare disease space, particularly in treatments for DMD.
PTC Therapeutics
PTCT
Mkt Cap5.43B
PTC Therapeutics offers treatment for DMD, competing directly with Sarepta's DMD therapies.
Solid Biosciences
SLDB
Mkt Cap711.53M
Solid Biosciences is focused on developing therapies for DMD, positioning it as a direct competitor to Sarepta.
Dyadic International DE
DYAI
Mkt Cap27.37M
Dyadic International is working on developing and manufacturing biopharmaceuticals for diseases that Sarepta also targets.
Vertex Pharmaceuticals
VRTX
Mkt Cap107.83B
Vertex Pharmaceuticals is involved in treating cystic fibrosis and other diseases, competing with Sarepta in the broader rare disease market.
Ultragenyx Pharmaceutical
RARE
Mkt Cap2.44B
Ultragenyx Pharmaceutical focuses on rare diseases, including some that overlap with Sarepta's target indications.
Biogen
BIIB
Mkt Cap27.62B
Biogen has a broad portfolio in neurology and rare diseases, competing with Sarepta in areas like gene therapy for neurological disorders.

About

There is no Profile data available for AB3A.SG.
Show more...
CEO
Mr. Douglas S. Ingram Esq., J.D.
Employees
1372
Country
United States
ISIN
US8036071004

Listings

MI
IT
1SRPT.MI
MX
MX
SRPT.MX
MU
DE
AB3A.MU
LSE
GB
0L35.LSE

0 Comments

Share your thoughts

FAQ

What is Sarepta Therapeutics stock price today?▼
The current price of SRPT is $21.79 USD — it has decreased by -1.13% in the past 24 hours. Watch Sarepta Therapeutics stock price performance more closely on the chart.
What is Sarepta Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Sarepta Therapeutics stocks are traded under the ticker SRPT.
Is Sarepta Therapeutics stock price growing?▼
SRPT stock has risen by +5.42% compared to the previous week, the month change is a -4.43% fall, over the last year Sarepta Therapeutics has showed a -53.39% decrease.
What is Sarepta Therapeutics market cap?▼
Today Sarepta Therapeutics has the market capitalization of 2.28B
What is Sarepta Therapeutics revenue for the last year?▼
Sarepta Therapeutics revenue for the last year amounts to 3.8B USD.
What is Sarepta Therapeutics net income for the last year?▼
SRPT net income for the last year is 470.48M USD.
How many employees does Sarepta Therapeutics have?▼
As of May 06, 2026, the company has 1,372 employees.
In which sector is Sarepta Therapeutics located?▼
Sarepta Therapeutics operates in the Health & Wellness sector.
When did Sarepta Therapeutics complete a stock split?▼
Sarepta Therapeutics has not had any recent stock splits.
Where is Sarepta Therapeutics headquartered?▼
Sarepta Therapeutics is headquartered in Cambridge, United States.